Prognostic value of IL-6 in localized prostatic cancer

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4369-4372

  Alcover, Juan ^a   Filella, Xavier ^a   Luqué, Pilar ^a   Molina, Rafael ^a   Izquierdo, Laura ^a   Augé, Josep Maria ^a   Alcaraz, Antonio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

IL 6; Prostatic cancer; Tumor marker

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL;

AGED; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-6; TUMOR MARKERS, BIOLOGICAL;

EID: 78650230741     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
2. Klein EA and Silverman R: Inflammation, infection, and prostate cancer. Curr Opin Urol 18: 315-319, 2008.
3. De Marzo, AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG: Inflammation in prostate carcinogenesis. Nature Reviews Cancer 7: 256-269, 2007.
4. Filella X, Alcover J, Zarco MA, Beardo P, Molina R and Ballesta AM: Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44: 271-274, 2000.
5. Kesarwani P, Ahirwar DK, Mandan A and Mittal RD: Association between -174 G-C promoter polymorphism of the interleukin-6 gene and progresión of prostate cancer in North Indian population. DNA Cell Biol 27: 505-510, 2008.
6. Cardillo MR and Ippoliti F: IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 26: 3409-3416, 2006.
7. Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312-2316, 2004.
8. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY and Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549, 1995.
9. Culig Z, Steiner H, Bartsch G and Hobisch A: Interleukin-6 regulation of prostate cancer cell growth. J Cellul Biochem 95: 497-505, 2005.
10. Culig Z: New insights into the role of interleukin-6 in human prostate cancer. J Urol 182: 1255-1256, 2009.
11. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR and Ornstein DK: Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 182: 1621-1627, 2009.
12. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL and Gao AC: Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174: 753-756, 2005.
13. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015, 2001.
14. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM and Slawin KM: The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21: 3573-3579, 2003.
15. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor β1 and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999, 2004.
16. Dennis LK, Lynch CF and Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78-83, 2002.
17. Sarma AV, McLaughlin JC, Wallner LP, Dunn RL, Cooney KA, Schottenfeld D, Montie JE and Wei JT: Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol 176: 1108-1113, 2006.
18. De Marzo, AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG: Inflammation in prostate carcinogenesis. Nature Reviews Cancer 7: 256-269, 2007.
19. Federico A, Morgillo F, Tuccillo C, Ciardiello F and Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 121: 2381-2386, 2007.
20. Faupel-Badger JM, Kidd LCR, Albanes D, Virtamo J, Woodson K and Tangrea JA: Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19: 119-124, 2008.
21. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA and Howell WM: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62: 3369-3372, 2002.
22. Lindmark F, Zheng SL, Wiklund F, Baiter KA, Sun J, Chang B, Hedelin M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Grönberg H and Xu J: Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93: 493-497, 2005. (Pubitemid 43080026)
23. Lin HC, Liu CC, Kang WY, Yu CC, Wu TT, Wang JS, Wu WJ, Huang CH, Wu MT and Huang SP: Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol Int 83: 463-470, 2009.
24. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H and Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706, 2000.
25. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58: 1008-1015, 2001.
26. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM and Karakiewicz PI: Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14: 3785-3791, 2008.
27. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM and Shariat SF: Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69: 886-894, 2009.
28. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A and Culig Z: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16: 155-169, 2009.
29. Mikolajczyk SD, Song Y, Wong JR, Matson RS and Rittenhouse HG: Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 37: 519-528, 2004.